Standout Papers

Dapagliflozin and Cardiov... 2012 2026 2016 2021 2018 2018 2018 2012 2019 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    2018 4.2k citations Stephen D. Wiviott, Itamar Raz et al. New England Journal of Medicine profile →
  2. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
    2018 1.9k citations Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet profile →
  3. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
    2018 822 citations Joe‐Elie Salem, Ali Manouchehri et al. The Lancet Oncology profile →
  4. Vorapaxar in the Secondary Prevention of Atherothrombotic Events
    2012 655 citations David A. Morrow, Eugene Braunwald et al. New England Journal of Medicine profile →
  5. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
    2019 526 citations Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation profile →
  6. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
    2017 484 citations Marc P. Bonaca, Patrice Nault et al. Circulation profile →
  7. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
    2020 307 citations Thomas A. Zelniker, Marc P. Bonaca et al. Circulation profile →
  8. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
    2025 21 citations Marc P. Bonaca, Andrei‐Mircea Catarig et al. The Lancet profile →

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 78 hit
Sub-graph 1 of 18

Citing Papers

Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial
2024 Hit
Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association
2023 Hit
2 intermediate papers

Works of Marc P. Bonaca being referenced

Microvascular Disease, Peripheral Artery Disease, and Amputation
2019
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
2016
and 8 more

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Marc P. Bonaca 7.0k 6.7k 5.8k 3.1k 2.1k 275 15.2k
Benjamin M. Scirica 5.7k 0.8× 12.6k 1.9× 6.6k 1.1× 2.5k 0.8× 1.2k 0.6× 274 19.2k
David Fitchett 12.7k 1.8× 5.9k 0.9× 6.8k 1.2× 5.2k 1.7× 1.9k 0.9× 200 18.5k
Kathy Wolski 6.1k 0.9× 3.5k 0.5× 8.7k 1.5× 3.5k 1.1× 1.4k 0.7× 111 16.4k
Mark C. Petrie 3.3k 0.5× 12.6k 1.9× 4.4k 0.8× 1.5k 0.5× 1.6k 0.7× 316 16.7k
S. Matthijs Boekholdt 5.2k 0.7× 5.1k 0.8× 6.5k 1.1× 1.5k 0.5× 871 0.4× 292 14.0k
Thomas Moritz 3.9k 0.6× 4.1k 0.6× 3.5k 0.6× 1.2k 0.4× 1.3k 0.6× 107 10.2k
John Dormandy 3.5k 0.5× 2.7k 0.4× 12.1k 2.1× 1.9k 0.6× 8.0k 3.7× 179 16.3k
Stefan Hantel 9.3k 1.3× 4.9k 0.7× 4.6k 0.8× 4.0k 1.3× 1.2k 0.6× 63 13.7k
Nihar R. Desai 3.0k 0.4× 4.2k 0.6× 3.4k 0.6× 1.1k 0.4× 602 0.3× 302 10.2k
Christian T. Ruff 4.3k 0.6× 9.2k 1.4× 2.6k 0.4× 1.9k 0.6× 860 0.4× 174 14.4k

All Works

Loading papers...

Rankless by CCL
2026